Sputnik V vaccine is now available in India
On 12th April 2021, DCGI has approved a Russian third coronavirus vaccine–Sputnik V. The decision comes after the Subject Expert Committee (SEC) met yesterday to take up Sputnik V application for Emergency Use Authorisation in India. The first two are Serum Institute of India’s locally-made Oxford Covid-19 vaccine ‘Covishield‘ and Bharat Biotech’s indigenously manufactured Covaxin.
Now, The Sputnik V vaccine would be imported from Russia for emergency use in the country.Sputnik V gives around 92% protection against Covid-19, late stage trial results published in The Lancet reveal.
On Sunday, top government sources told news agency ANI that by end of the third quarter of this year, India will be getting vaccines from five additional manufacturers. India currently manufactures Covishield and Covaxin. These vaccines are the Sputnik V vaccine (in collaboration with Dr. Reddy’s), Johnson & Johnson vaccine (in collaboration with Biological E), Novavax vaccine (in collaboration with Serum India), Zydus Cadila’s vaccine, and Bharat Biotech’s Intranasal Vaccine.
Out of almost 20 COVID-19 vaccines in various clinical and pre-clinical stages, Sputnik V vaccine will get the nod first. It is expected that Sputnik is likely to get the EUA within the next ten days, it had said.
In India, Sputnik-V trials are on for around 1,600 people between 18 and 99.
Russian Direct Investment Fund (RDIF) has tied up with a host of Indian pharmaceutical players such as Panacea Biotec, Dr Reddy’s Laboratories and Gland Pharma for the production of vaccine doses.
Dr.Reddy’s has been conducting small clinical trials with Sputnik V in India under a deal with Russia’s wealth fund since last September. Several Indian companies have signed deals to produce and supply over half a billion doses of the vaccine.
What is a Sputnik V VACCINE?
The Sputnik V vaccine, developed by Gamaleya National Research Institute of Epidemiology and Microbiology in Moscow, uses two different viruses that cause the common cold (adenovirus) in humans. The adenoviruses are weakened so they cannot replicate in humans and cannot cause disease. They are also modified so that the vaccine delivers a code for making the coronavirus spike protein. This aims to ensure that when the real virus tries to infect the body, it can mount an immune response in the form of antibodies.
Sputnik uses a different vector for each of the two shots in a course of vaccination. This provides immunity with a longer duration than vaccines using the same delivery mechanism for both shots, according to the Russian Direct Investment Fund (RDIF). The two shots are given 21 days apart.
Sputnik V is to be stored at -18°C in its liquid form. However, in its freeze-dried form, it can be stored at 2-8°C, without any need to invest in additional cold-chain infrastructure. Sputnik V is approved for use in over 55 countries.